Literature DB >> 3263583

Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease.

J Rogers1, J Luber-Narod, S D Styren, W H Civin.   

Abstract

HLA-DR is a class II major histocompatibility complex antigen which in the periphery confers antigen presenting capability. We have previously shown that this marker is profusely expressed in cortex of elderly and Alzheimer's disease (AD) patients, as is the receptor for the lymphokine interleukin-2. We now report presence of additional immune-related antigens in AD, and distributional differences from normal elderly controls. In gray matter, HLA-DR immunoreactivity is normally sparse, except in AD where it co-localizes with virtually all neuritic plaques. HLA-DR positive T cells can be demonstrated in Alzheimer's disease brain tissue, as can instances of apposition between putative brain microglia and T cells. In addition, cells with the morphologic characteristics of astrocytes label for natural killer cell antigen (Leu-11), and apparent lymphocytes bearing T helper and T cytotoxic/suppressor cell antigens are observed. These and other data suggest that the glial proliferation and scavenger activity characteristic of Alzheimer's disease may occur in an immune context and may play an important role in the pathogenesis of the disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263583     DOI: 10.1016/s0197-4580(88)80079-4

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  196 in total

1.  Microglia in Alzheimer's disease and transgenic models. How close the fit?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia.

Authors:  W G Kim; R P Mohney; B Wilson; G H Jeohn; B Liu; J S Hong
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

3.  Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid.

Authors:  S A Frautschy; G M Cole; A Baird
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

Review 4.  Aging-related changes in neuroimmune-endocrine function: implications for hippocampal-dependent cognition.

Authors:  Ruth M Barrientos; Matthew G Frank; Linda R Watkins; Steven F Maier
Journal:  Horm Behav       Date:  2012-02-18       Impact factor: 3.587

Review 5.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

6.  Microglial TNF-α-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration.

Authors:  Yi-Ming Yang; De-Shu Shang; Wei-Dong Zhao; Wen-Gang Fang; Yu-Hua Chen
Journal:  Neurochem Res       Date:  2013-08-29       Impact factor: 3.996

7.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

Review 8.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

10.  Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia.

Authors:  D Giulian; L J Haverkamp; J H Yu; W Karshin; D Tom; J Li; J Kirkpatrick; L M Kuo; A E Roher
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.